Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 66 Results

Title
Intervention Indication Therapeutic Area Year Actions
Semaglutide for treating peripheral arterial disease (PAD) and type 2 diabetes Semaglutide (Ozempic) Peripheral arterial disease (PAD) , Type 2 diabetes Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Semaglutide for treating overweight or obesity with cardiovascular disease Semaglutide (Ozempic) Cardiovascular disease (CVD) , Obesity Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2023 View  |  Download
Semaglutide for treating obesity-related heart failure Semaglutide (Ozempic) Obesity-related heart failure Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan) Post-acute myocardial infarction (MI) Cardiovascular System 2021 View  |  Download
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children Sacubitril-valsartan Chronic heart failure Cardiovascular System 2022 View  |  Download
Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure Rivaroxaban (Xarelto; BAY 59-7939) Peripheral arterial disease (PAD) Cardiovascular System 2019 View  |  Download
Rivaroxaban for prevention of cardiovascular events following an episode of decompensated heart failure Rivaroxaban (Xarelto; BAY 59-7939) Heart failure (HF) Cardiovascular System 2018 View  |  Download
Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease Rivaroxaban (Xarelto; BAY 59-7939) Cardiovascular disease (CVD) Cardiovascular System 2017 View  |  Download
Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) Rituximab (MabThera; Rituxan; RG 105) Granulomatosis with polyangiitis (GPA) , Microscopic polyangiitis (MPA) Cardiovascular System 2017 View  |  Download
Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus REX-001 (Rexmyelocel-T) Critical limb ischaemia (CLI) Cardiovascular System 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications